<SEC-DOCUMENT>0001193125-26-274139.txt : 20260617
<SEC-HEADER>0001193125-26-274139.hdr.sgml : 20260617
<ACCEPTANCE-DATETIME>20260617160545
ACCESSION NUMBER:		0001193125-26-274139
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260616
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260617
DATE AS OF CHANGE:		20260617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImageneBio, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811697316
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40287
		FILM NUMBER:		261098359

	BUSINESS ADDRESS:	
		STREET 1:		12526 HIGH BLUFF DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		12526 HIGH BLUFF DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ikena Oncology, Inc.
		DATE OF NAME CHANGE:	20201208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d114862d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ima="http://www.ikenaoncology.com/20260616" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2026-06-16_to_2026-06-16">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-401">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-06-16_to_2026-06-16">0001835579</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ima-20260616.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-06-16_to_2026-06-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-06-16</xbrli:startDate> <xbrli:endDate>2026-06-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-412">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt:datemonthdayyearen" id="ixv-413">June&#160;16, 2026</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-414">IMAGENEBIO, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:stateprovnameen" id="ixv-415">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-416">001-40287</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-417">81-1697316</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-418">12526 High Bluff Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-419">Suite 345</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-420">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:stateprovnameen" id="ixv-421">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-422">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-423">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-424">345-6265</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:boolballotbox" id="ixv-425">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:boolballotbox" id="ixv-426">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:boolballotbox" id="ixv-427">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:boolballotbox" id="ixv-428">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-429">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-430">IMA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:boolballotbox" id="ixv-431">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2026-06-16_to_2026-06-16" format="ixt-sec:boolballotbox" id="ixv-432">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;16, 2026, ImageneBio, Inc. (the &#8220;Company&#8221;) held its 2026 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). As further described in Item 5.07 below, the stockholders of the Company approved an amendment and restatement of the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;) at the Annual Meeting to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2025 Plan by 850,000 shares and to include shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants in the calculation of the annual automatic share reserve increase (the &#8220;Amended Plan&#8221;). The Company&#8217;s Board of Directors had previously approved the amendment and restatement of the 2025 Plan, subject to stockholder approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A description of the material terms of the Amended Plan is contained in the section entitled &#8220;Proposal 3: Approval of the Amendment and Restatement of the 2025 Equity Incentive Plan&#8221; of the Company&#8217;s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April&#160;30, 2026 (the &#8220;Proxy Statement&#8221;). That description is incorporated into this Item 5.02 by reference. Such description, as well as the foregoing description in this Item&#160;5.02, does not purport to be complete, and are qualified in their entirety by reference to the full text of the Amended Plan, which is attached hereto as Exhibit 10.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.07</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Submission of Matters to a Vote of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company held its Annual Meeting on June&#160;16, 2026. As of April&#160;28, 2026, the record date for the Annual Meeting, there were 11,279,130 outstanding shares of the Company&#8217;s voting common stock. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal 1: Election of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders elected the following two individuals to serve as Class&#160;II directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified or until his earlier death, resignation or removal. The final voting results are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">For</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Withheld</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David P. Bonita, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,980,671</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40,117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">612,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph P. Slattery</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,985,414</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">35,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">612,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders ratified the appointment by the Audit Committee of the Company&#8217;s Board of Directors of PricewaterhouseCoopers LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2026. The final voting results are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center">7,613,075</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center">20,477</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center">5</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal 3: 2025 Amended Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders approved the Amended Plan. The final voting results are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center">6,322,909</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center">591,191</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center">106,688</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center">612,769</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d114862dex101.htm">ImageneBio, Inc. Amended and Restated 2025 Equity Incentive Plan. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">IMAGENEBIO, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;17, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kristin Yarema</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Kristin Yarema, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d114862dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I<SMALL>MAGENE</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
D<SMALL>ECEMBER</SMALL>&nbsp;12, 2024 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
J<SMALL>ULY</SMALL>&nbsp;15, 2025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL>
<SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;27, 2026 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>UNE</SMALL>&nbsp;16, 2026 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>
<B>Successor to and Continuation of Prior Plan.</B> The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i)&nbsp;no additional awards may be granted under the Prior Plan; (ii)&nbsp;any Returning Shares will
become available for issuance pursuant to Awards granted under this Plan; and (iii)&nbsp;all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in
Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Plan Purpose.</B> The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and
Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common
Stock through the granting of Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Available Awards.</B> The Plan provides for the grant of the following Awards:
(i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date, but no Award may be granted prior to
the Effective Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as necessary to implement any
Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of: (i)&nbsp;850,000 shares that were approved at the Company&#8217;s 2026 Annual Meeting of Stockholders, plus
(ii) 1,118,167 shares initially reserved under the Plan, plus (iii) 559,081 shares that were added pursuant to the annual automatic share increase on January&nbsp;1, 2026, plus (iv)&nbsp;up to 0 Returning Shares, as such shares become available from
time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January&nbsp;1 of each year for a period of ten years
commencing on January&nbsp;1, 2027 and ending on (and including) January&nbsp;1, 2036, in an amount equal to five percent (5%) of the sum of (x)&nbsp;the total number of shares of Common Stock outstanding on December 31<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> of the preceding calendar year plus (y)&nbsp;the total number of shares of Common Stock issuable upon conversion of shares of Convertible Preferred Stock outstanding on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the preceding calendar year plus (z)&nbsp;the total number of shares of Common Stock issuable upon cash exercise of Prefunded
Warrants outstanding on December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the preceding calendar year; provided, however, that the Board may act prior to January 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of a given
year to provide that the increase for such year will be a lesser number of shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Aggregate Incentive Stock
Option Limit.</B> Notwithstanding anything to the contrary in Section&nbsp;2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued
pursuant to the exercise of Incentive Stock Options is 7,581,744 shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Share Reserve Operation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the number of shares of
Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue
shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company Guide
Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The following actions do not result
in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the expiration or termination of any portion of an Award without the shares
covered by such portion of the Award having been issued; (2)&nbsp;the settlement of any portion of an Award in cash (<I>i.e.</I>, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be issued
by the Company to satisfy the exercise, strike or purchase price of an Award; or (4)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock previously
issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by
the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&nbsp;any
shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. E<SMALL>LIGIBILITY</SMALL>
<SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Eligible Award Recipients.</B> Subject to the terms of the Plan,
Employees, Directors and Consultants are eligible to receive Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees of the Company or
a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Incentive Stock Option $100,000 Limitation.</B> To the extent that the aggregate Fair Market Value (determined at the time of
grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit
established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such
rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</B> A Ten Percent Stockholder may not be granted an
Incentive Stock Option unless (1)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (2)&nbsp;the Option is not exercisable after the expiration of five years from the date of
grant of such Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Limitations on Nonstatutory Stock Options and SARs.</B> Nonstatutory Stock Options and SARs may not
be granted to Employees, Directors and Consultants unless the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section&nbsp;409A or unless such Awards otherwise comply with the requirements of Section&nbsp;409A.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of shares of Common Stock that may be issued
pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
with respect to any calendar year, including Awards granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (1) $750,000 in total value or (2)&nbsp;in the event such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board during such calendar year, $1,000,000 in total value, in each case, calculating the value of any equity awards based on the grant date fair value of
such equity awards for financial reporting purposes.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be
designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify as an Incentive
Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and
conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the
substance of each of the following provisions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, no
Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of
each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on
the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A
and, if applicable, 424(a) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Exercise Procedure and Payment of Exercise Price for Options.</B> In order to
exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that
do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option
may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash or check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation T as promulgated by the U.S. Federal Reserve Board
that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the
Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common Stock is
publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not violate any Applicable Law or agreement
restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the Participant for any minimum period
necessary to avoid adverse accounting treatment as a result of such delivery; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221;
arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price,
provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted
form of payment; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of consideration that may be acceptable to the Board and permissible under Applicable
Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Exercise Procedure and Payment of Appreciation Distribution for SARs</B><B>.</B> In order to exercise any SAR, the
Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of
(i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii)&nbsp;the strike price of such SAR.
Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Transferability.</B> Options and SARs may not be transferred to third party financial institutions for value. The Board may
impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that
except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and <I>provided, further</I>, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a
result of such transfer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Transfer.</B> An Option or SAR will not be transferable, except by will or by the
laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax
and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code and applicable state law) while such
Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format
acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the
Participant&#8217;s Continuous Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Termination of Continuous Service for Cause.</B> Except as explicitly
otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate
and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous
Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if
applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its
maximum term (as set forth in Section&nbsp;4(a)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> three months following the date of such termination if such termination is a
termination without Cause (other than any termination due to the Participant&#8217;s Disability or death); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> 12 months following
the date of such termination if such termination is due to the Participant&#8217;s Disability; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> 12 months following the date
of such termination if such termination is due to the Participant&#8217;s death; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> 12 months following the date of the
Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or,
if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock
subject to the terminated Award, or any consideration in respect of the terminated Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Exercise;
Extension of Exercisability. </B>A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other
written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination
Exercise Period: (i)&nbsp;the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii)&nbsp;the immediate sale of any shares
of Common Stock issued upon such exercise would violate the Company&#8217;s Trading Policy, then the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the
exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided,
however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&nbsp;4(a)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B><B>.</B> No Option or SAR, whether or not vested, granted to an
Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the U.S. Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the
date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the U.S. Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such
Award in the event of (i)&nbsp;such Participant&#8217;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&#8217;s
retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current employment policies and guidelines). This Section&nbsp;4(j)
is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Whole Shares.</B> Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Restricted Stock Awards and RSU Awards.</B> Each Restricted Stock
Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in
the Award Agreement or otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Form of Award.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Restricted Stock Awards: To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of Common
Stock subject to a Restricted Stock Award may be (A)&nbsp;held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (B)&nbsp;evidenced by a certificate, which certificate
will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock
Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU Awards: An RSU Award represents a Participant&#8217;s right to be issued on a future date the number of shares of
Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded obligation, if any, to issue
shares of Common Stock in settlement of such Award and nothing contained in the Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any RSU Award Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the
Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Consideration.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money
order payable to the Company, (B)&nbsp;services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the
Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any
shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the
issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Vesting. </B>The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the
Participant&#8217;s Continuous Service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Termination of Continuous Service.</B> Except as otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (1)&nbsp;the Company may receive through a forfeiture condition or a repurchase right
any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no
further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (2)&nbsp;any portion of his or her RSU Award that has
not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>Dividends and Dividend Equivalents. </B>Dividends or dividend equivalents may be paid or credited, as applicable, with
respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B>Settlement of RSU Awards.</B> An RSU Award may be settled by the issuance of
shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions
that delay such delivery to a date following the vesting of the RSU Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Performance Awards.</B> With respect to any
Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been
attained will be determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Other Awards.</B> Other forms of Awards valued in whole or in part by reference
to, or otherwise based on, Common Stock, including the appreciation in value thereof may be granted either alone or in addition to Awards provided for under Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the
provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be
granted pursuant to such Other Awards and all other terms and conditions of such Other Awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL>
C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Capitalization Adjustments</B><B>.</B> In the event of a Capitalization Adjustment, the Board shall appropriately and
proportionately adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&nbsp;2(a); (ii) the class(es) and
maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b); and (iii)&nbsp;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock
subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created
in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding
provisions of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Dissolution or Liquidation.</B> Except as otherwise provided in the Award Agreement, in the
event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will
terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Corporate Transaction. </B>The following provisions will apply to Awards in
the event of a Corporate Transaction, except as set forth in Section&nbsp;11, unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless
otherwise expressly provided by the Board at the time of grant of an Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a
Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for
Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company
in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or
acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue or substitute the Awards held by some, but not all
Participants. The terms of any assumption, continuation or substitution will be set by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Awards Held by Current
Participants.</B> In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding
Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the
&#8220;<B><I>Current Participants</I></B>&#8221;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will<B> </B>be accelerated in full to a date prior to the
effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the
Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will
lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have
multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in
which the Awards are not assumed, continued or substituted in accordance with Section&nbsp;6(c)(i). With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and
are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction or such later date as required to comply with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Awards Held by Persons other than Current Participants.</B> In the event of a Corporate Transaction in which the surviving
corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate
Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event an Award will terminate if not exercised
prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in
value, at the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over
(2)&nbsp;any exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Appointment of Stockholder
Representative.</B> As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Restriction on Right to Undertake Transactions.</B> The grant of any Award under the Plan and the issuance of shares pursuant
to any Award does not affect or restrict in any way the right or power of the Company, the Board or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital
structure or its business, any Change in Control, any Corporate Transaction, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference
stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its
assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan
to a Committee or Committees, as provided in subsection (c)&nbsp;below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power, subject to, and within the
limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to time (1)&nbsp;which of the persons eligible under
the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be identical), including the time
or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such
person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or
other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and interpret the Plan and Awards granted under it,
and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it
deems necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all controversies regarding the Plan and
Awards granted under it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To accelerate the time at which an Award may first be exercised or the time during which an Award or
any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of
any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or
the share price of the Common Stock, including any Corporate Transaction, for reasons of administrative convenience. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> To amend the Plan in any respect the Board deems necessary or advisable; provided, however<I>,</I> that stockholder approval will
be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&nbsp;the Company
requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To submit any amendment
to the Plan for stockholder approval. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of
any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board
discretion; <I>provided however</I>, that, a Participant&#8217;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant
consents in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> Generally, to exercise such powers and to perform such acts as the Board deems
necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit and
facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals or employed outside the United States
(provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xii)</B> To effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such
action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A)&nbsp;a new Option, SAR, Restricted
Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable consideration (as determined by the Board);
or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Delegation to
Committee. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the
power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee),
subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee
to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at
any time, revest in the Board some or all of the powers previously delegated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> To the extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of
the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT>
of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Effect of Board</B><B>&#8217;</B><B>s Decision.</B> All determinations, interpretations and constructions made by the Board or
any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Delegation to Other Person or Body.</B> The Board or any Committee may
delegate to one or more persons or bodies the authority to do one or more of the following to the extent permitted by Applicable Law: (i)&nbsp;designate recipients, other than Officers, of Awards, provided that no person or body may be delegated
authority to grant an Award to themself; (ii)&nbsp;determine the number of shares subject to such Awards; and (iii)&nbsp;determine the terms of such Awards; provided, however, that the Board or Committee action regarding such delegation will fix the
terms of such delegation in accordance with Applicable Law, including without limitation Sections 152 and 157 of the Delaware General Corporation Law. Unless provided otherwise in the Board or Committee action regarding such delegation, each Award
granted pursuant to this section will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications necessary to incorporate or reflect the terms of such Award.
Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to any person or body (who is not a Director or that is not comprised solely of Directors, respectively) the authority to determine the Fair Market
Value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding
from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate arrangements to satisfy the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding obligations, if any, of the Company and/or an
Affiliate that arise in connection with the grant, vesting, exercise or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no
obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding obligation relating
to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the
Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a
&#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the U.S. Federal Reserve Board; or (vi)&nbsp;by such other method as may be set forth in the Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes; No Liability to Claims. </B>Except as required by Applicable Law, the Company has no
duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an
Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax
consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates
related to tax liabilities arising from such Award or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company compensation and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of
the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section&nbsp;409A only if the exercise or strike price is at least
equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the U.S. Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a
condition to accepting an Option or SAR granted under the Plan, each Participant agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the U.S. Internal Revenue Service asserts
that such exercise price or strike price is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Withholding Indemnification. </B>The Company and/or its Affiliate may withhold or account for
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering statutory or other withholding rates, including minimum or maximum rates applicable in a Participant&#8217;s jurisdiction. In the event of overwithholding, the Participant may
receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock) or, if not refunded, the Participant may seek a refund from the local tax authorities. In the event of under-withholding, the Participant
may be required to pay any additional <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items directly to the applicable tax authority or to the Company and/or its Affiliate. As a condition to accepting an Award under the Plan, in the event that
the amount of the Company&#8217;s and/or its Affiliate&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the
Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. Further, if the obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in
shares of Common Stock, for tax purposes, the Participant will be deemed to have been issued the full number of shares subject to the Award, notwithstanding that a number of the shares is held back solely for the purpose of paying the <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. M<SMALL>ISCELLANEOUS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Use of Proceeds from Sales of Common Stock.
</B>Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board,
regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes)
documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the
Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or
to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and
(ii)&nbsp;the issuance of the Common Stock subject to such Award is reflected in the records of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Employment
or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or
an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will (unless otherwise required under Applicable Law) and without regard to any future vesting opportunity
that a Participant may have with respect to any Award (i)&nbsp;the employment of an Employee with or without notice and with or without Cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the
Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or
commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the
Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Change in
Time Commitment.</B> In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee
of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted
by Applicable Law, to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in
lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or
extended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Execution of Additional Documents.</B> As a condition to accepting an Award under the Plan, the Participant agrees
to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other
regulatory requirements, in each case at the Plan Administrator&#8217;s request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Electronic Delivery and Participation.</B> Any reference herein or in an Award
Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared
electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any
<FONT STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or
electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Clawback/Recovery.</B> All Awards granted under
the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are
listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In
addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares
of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntarily terminate employment upon a
&#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Securities Law Compliance. </B>A Participant will not be issued any shares in respect of an Award unless either (i)&nbsp;the
shares are registered under the Securities Act or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the
Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the Plan or the form of Award Agreement,
Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of a Restricted Stock Award and similar awards, after the issued shares have vested,
the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and
Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>Effect on Other Employee Benefit Plans. </B>The value of any Award granted under the Plan, as determined
upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate,
except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of
Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made
in accordance with the requirements of Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>Section 409A. </B>Unless otherwise expressly provided for in an Award
Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and, to the extent not so exempt, in compliance with the
requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions
necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.
Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred
compensation&#8221; under Section&nbsp;409A is a &#8220;specified employee&#8221; for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in
Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the
date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the
balance paid thereafter on the original schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>Choice of Law</B><B>. </B>This Plan and any controversy arising out of or
relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of
Delaware. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan
such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the
Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for
the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and
until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL>
S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Application. </B>Unless the provisions of this Section of the Plan are expressly
superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following provisions of this subsection (b)&nbsp;apply. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the ordinary course during the Participant&#8217;s
Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, in no event will the shares
be issued in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year that includes the applicable vesting
date; or (ii)&nbsp;the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
If vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#8217;s Separation from Service,
and such vesting acceleration provisions were in effect as of the date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award as
of the date of grant, then the shares will be earlier issued in settlement of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the date of the Participant&#8217;s Separation from Service. However, if at
the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &#8220;specified employees,&#8221; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such
shares shall not be issued before the date that is six months following the date of such Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such
<FONT STYLE="white-space:nowrap">six-month</FONT> period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Award accelerates under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the
date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award on the date of grant, then such acceleration of vesting of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course
during the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified
date or pursuant to a fixed schedule, as provided under U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for Employees and
Consultants.</B> The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in
connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The
following provisions shall apply to any Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> If the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or
substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control the settlement of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and
the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market
Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the
Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of
the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not
occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be
issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and forfeiture restrictions that were
applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule
that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each
applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the Acquiring Entity will not assume, substitute or continue any Unvested
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in
respect of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its discretion
determine to elect to accelerate the vesting and settlement of the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares
that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be forfeited
without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate Transaction.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> The foregoing treatment shall apply with respect to all Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of
a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the
Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change in Control
the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If the Corporate Transaction is
not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In
the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to
the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, then the provisions in this Section&nbsp;11(e) shall
apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Any exercise by the Board of discretion to accelerate the vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award
shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless earlier issuance of the shares upon the applicable vesting dates would be in
compliance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The Company explicitly reserves the right to earlier settle any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available in U.S. Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent the terms of any
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in Control
or Corporate Transaction event triggering settlement must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a termination
of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at
the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &#8220;specified
employees,&#8221; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#8217;s Separation From Service, or, if earlier, the date of the
Participant&#8217;s death that occurs within such six month period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The provisions in this subsection (e)&nbsp;for delivery of
the shares in respect of the settlement of an RSU Award that is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the Participant in
respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. S<SMALL>EVERABILITY</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all
or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be
unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a
Section to the fullest extent possible while remaining lawful and valid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the
tenth anniversary of the earlier of: (i)&nbsp;the Adoption Date; or (ii)&nbsp;the date the Plan is approved by the Company&#8217;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#8220;<B><I>Acquiring Entity</I></B>&#8221; means the surviving or acquiring corporation (or its parent company) in connection with
a Corporate Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#8220;<B><I>Adoption Date</I></B>&#8221; means the date the Plan is first approved by the Board or
Compensation Committee, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#8220;<B><I>Affiliate</I></B>&#8221; means, at the time of determination, any
&#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#8220;<B><I>Applicable Law</I></B>&#8221; means the Code and any applicable U.S
and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities, exchange, control, tax, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule,
listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable
self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#8220;<B><I>Award</I></B>&#8221; means any right to receive Common Stock, cash or other property granted under the Plan (including
an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#8220;<B><I>Award Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a Participant evidencing
the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through
electronic means, to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#8220;<B><I>Board</I></B>&#8221; means the Board of Directors
of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding
on all Participants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#8220;<B><I>Capital Stock</I></B>&#8221; means each and every class of common stock of the Company,
regardless of the number of votes per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <I>&#8220;</I><B><I>Capitalization Adjustment</I></B>&#8221; means any change that
is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).
Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#8220;<B><I>Cause</I></B>&#8221;<B><I> </I></B>has the meaning ascribed to such term in any written agreement between a Participant
and the Company or any Affiliate of the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;the Participant&#8217;s dishonest
statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii)&nbsp;the Participant&#8217;s commission of
(A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or in each case the equivalent in any relevant jurisdiction; (iii)&nbsp;the Participant&#8217;s failure to perform the Participant&#8217;s assigned
duties and responsibilities to the reasonable satisfaction of the Company or any Affiliate of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company or any
Affiliate of the Company; (iv)&nbsp;the Participant&#8217;s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v)&nbsp;the Participant&#8217;s material violation of any provision
of any agreement(s) between the Participant and the Company or any Affiliate of the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#8217;s
Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#8217;s Chief Executive Officer with respect to Participants who are not
executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any
determination of the rights or obligations of the Company or any Affiliate of the Company or such Participant for any other purpose. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#8220;<B><I>Change in Control</I></B>&#8221; or &#8220;<B><I>Change of Control</I></B>&#8221; means the occurrence, in a single
transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes
the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an
investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance
of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#8220;<I>Subject Person</I>&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a
repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting
securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving
(directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A)&nbsp;outstanding voting securities representing more than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting
power of the parent of the Acquiring Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
transaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined
voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or
other disposition; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> individuals who, on the Adoption Date, are members of the Board (the &#8220;<B><I>Incumbent
Board</I></B>&#8221;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a
majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate
and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement,
the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also
constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#8220;<B><I>Code</I></B>&#8221; means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#8220;<B><I>Committee</I></B>&#8221; means the Compensation Committee and any other committee of one or
more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#8220;<B><I>Common Stock</I></B>&#8221; means the common stock of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#8220;<B><I>Company</I></B>&#8221; means Ikena Oncology, Inc., a Delaware corporation, and as of the Effective Date, shall
mean ImageneBio, Inc., a Delaware corporation, and any successor corporation thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#8220;<B><I>Compensation
Committee</I></B>&#8221; means the Compensation Committee of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#8220;<B><I>Consultant</I></B>&#8221; means any
person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is
compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is
treated as a Consultant under this Plan only if a Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such
person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#8220;<B><I>Continuous Service</I></B>&#8221; means that the Participant&#8217;s service with the Company or an
Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the
Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; provided,
however<I>,</I> that<I> </I>if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such
Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by
Applicable Law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the
Company or an Affiliate, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous
Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise
required by Applicable Law. In addition, to the extent required for exemption from or compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed,
in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under U.S. Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition
thereunder). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#8220;<B><I>Convertible Preferred Stock</I></B>&#8221; means the preferred stock of the Company that is
convertible into shares of Capital Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#8220;<B><I>Corporate Transaction</I></B>&#8221; means the consummation, in a
single transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other
disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of at least 50% of the outstanding securities of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Corporate Transaction shall not include a
sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Corporate Transaction (or any analogous term) in an individual written agreement between the Company
or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any analogous term is set forth in such an
individual written agreement, the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event described in clause (i),
(ii), (iii), or (iv)&nbsp;also constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#8220;<B><I>determine</I></B>&#8221; or &#8220;<B><I>determined</I></B>&#8221;<B><I> </I></B>means as determined by the Board or
the Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#8220;<B><I>Director</I></B>&#8221; means a member of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#8220;<B><I>Disability</I></B>&#8221; means, with respect to a Participant, such Participant is unable to engage in any substantial
gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in
Section&nbsp;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#8220;<B><I>Effective Date</I></B>&#8221; means the date of the closing of the transactions contemplated by that Agreement and Plan
of Merger, dated December&nbsp;23, 2024, between the Ikena Oncology, Inc., Insight Merger Sub I, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena
Oncology, Inc., Insight Merger Sub II, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena Oncology, Inc., and Inmagene Biopharmaceuticals, an exempted
company with limited liability incorporated and existing under the laws of the Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#8220;<B><I>Employee</I></B>&#8221; means any person employed by the Company or
an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#8220;<B><I>Employer</I></B>&#8221; means the Company or the Affiliate that employs the Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#8220;<B><I>Entity</I></B>&#8221; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#8220;<B><I>Exchange Act</I></B>&#8221; means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#8220;<B><I>Exchange Act Person</I></B>&#8221;<B><I> </I></B>means any natural person, Entity or
&#8220;group&#8221; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of
the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company, or (v)&nbsp;any natural person,
Entity or &#8220;group&#8221; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company&#8217;s then outstanding securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#8220;<B><I>Fair Market Value</I></B>&#8221; means, as of
any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#8220;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#8221; means any: (i)&nbsp;nation, state, commonwealth, canton,
province, territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;U.S. or <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;federal,</FONT> state, local, municipal, or other government; (iii)&nbsp;governmental or
regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit,
body or Entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or&nbsp;(iv)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York
Stock Exchange, and the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#8220;<B><I>Grant Notice</I></B>&#8221; means the notice provided to a
Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment
right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B>
&#8220;<B><I>Incentive Stock Option</I></B>&#8221; means an option granted pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&nbsp;422 of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#8220;<B><I>Materially Impair</I></B>&#8221;<B><I> </I></B>means any amendment to the terms of the Award that materially
adversely affects the Participant&#8217;s rights under the Award. A Participant&#8217;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the
amendment, taken as a whole, does not materially impair the Participant&#8217;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#8217;s rights under the Award:
(i)&nbsp;imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised; (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the
Code; (iii)&nbsp;to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iv)&nbsp;to clarify the
manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A; or (v)&nbsp;to comply with other Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#8221;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#8220;<B><I>Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT></I></B>&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a
business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT>
director&#8221; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221;<B><I> </I></B>means any Award that is subject to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the
Award which is elected by the Participant or imposed by the Company, or (ii)&nbsp;the terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#8221; means a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance
Arrangement</I></B>&#8221; means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the
Participant&#8217;s termination of employment or separation from service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder)) (&#8220;<B><I>Separation from
Service</I></B>&#8221;) and such severance benefit does not satisfy the requirements for an exemption from application of Section&nbsp;409A provided under U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT>
<FONT STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#8220;<B><I>Nonstatutory Stock Option</I></B>&#8221;
means any option granted pursuant to Section&nbsp;4 of the Plan that does not qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B>
&#8220;<B><I>Officer</I></B>&#8221; means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#8220;<B><I>Option</I></B>&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common
Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#8220;<B><I>Option Agreement</I></B>&#8221; means a written or electronic agreement
between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions
applicable to the Option and which is provided including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#8220;<B><I>Optionholder</I></B>&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#8220;<B><I>Other Award</I></B>&#8221; means an award valued in whole or in
part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) that is not an
Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B>
&#8220;<B><I>Other Award Agreement</I></B>&#8221;<B><I> </I></B>means a written or electronic agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will
be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#8220;<B><I>Own,</I></B>&#8221;<B><I>
</I></B>&#8220;<B><I>Owned,</I></B>&#8221;<B><I> </I></B>&#8220;<B><I>Owner,</I></B>&#8221; or<B><I> </I></B>&#8220;<B><I>Ownership</I></B>&#8221;<B> </B>means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221;
to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power,
which includes the power to vote or to direct the voting, with respect to such securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B>
&#8220;<B><I>Participant</I></B>&#8221; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#8220;<B><I>Performance Award</I></B>&#8221; means an Award that may vest or
may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section&nbsp;5(b) pursuant to
such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards.
Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#8220;<B><I>Performance Criteria</I></B>&#8221; means one or more criteria that the Board will select for purposes of establishing
the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including earnings per
share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; relative stockholder return; return on equity or average stockholder&#8217;s equity;
return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; <FONT STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash
flow; sales, annual recurring revenue or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market
share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#8217; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income
or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress of partnered programs; partner
satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the U.S. Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or completion of projects or
processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual
property); establishing relationships with respect to the marketing, distribution and sale of the Company&#8217;s products; supply chain achievements; co-development, <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint
venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee whether or not listed herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#8220;<B><I>Performance Goals</I></B>&#8221; means, for a Performance Period, one or more goals established by the Board for the
Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the
performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting
forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude
restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to
corporate tax rates; (5)&nbsp;to exclude the effects of items </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions
or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in
the outstanding shares of Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other
similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#8217;s bonus plans; (10)&nbsp;to exclude
costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required
to be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance
Goals at the time the Performance Goals are established. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the
Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written
terms of a Performance Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#8220;<B><I>Performance Period</I></B>&#8221; means the period of time selected by the Board
over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole
discretion of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#8220;<B><I>Plan</I></B>&#8221; means this Ikena Oncology, Inc. Amended and Restated 2025 Equity
Incentive Plan, as amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#8220;<B><I>Plan Administrator</I></B>&#8221; means the person, persons,
and/or third-party administrator designated by the Company to administer the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Plan and the Company&#8217;s other equity incentive programs.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> &#8220;<B><I>Post-Termination Exercise Period</I></B>&#8221; means the period following termination of a Participant&#8217;s
Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc)</B> &#8220;<B><I>Prefunded
Warrants</I></B>&#8221; means warrants to purchase shares of Common Stock where all but a nominal portion of the exercise price is prefunded by the purchasers of the warrants in connection with the sale and issuance of such warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd)</B> &#8220;<B><I>Prior Plan</I></B>&#8221; means the Ikena Oncology, Inc. 2021 Stock Option and Incentive Plan, as amended from time
to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(eee)</B> &#8220;<B><I>Prospectus</I></B>&#8221; means the document containing the Plan information specified in
Section&nbsp;10(a) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(fff)</B> &#8220;<B><I>Restricted Stock Award</I></B>&#8221; or
&#8220;<B><I>RSA</I></B>&#8221; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ggg)</B> &#8220;<B><I>Restricted Stock Award Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a
holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary
of the general terms and conditions applicable to the Restricted Stock Award and which is provided including by electronic means, to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and
conditions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hhh)</B> &#8220;<B><I>Returning Shares</I></B>&#8221; means shares subject to outstanding stock awards granted
under the Prior Plan and that following the Effective Date:&nbsp;(A)&nbsp;are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been
issued;&nbsp;(B)&nbsp;are not issued because such stock award or any portion thereof is settled in cash;&nbsp;(C)&nbsp;are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the
vesting of such shares;&nbsp;(D)&nbsp;are withheld or reacquired to satisfy the exercise, strike or purchase price; or&nbsp;(E)&nbsp;are withheld or reacquired to satisfy a tax withholding obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> &#8220;<B><I>RSU Award</I></B>&#8221; or &#8220;<B><I>RSU</I></B>&#8221;<B><I> </I></B>means an Award of restricted stock units
representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jjj)</B> &#8220;<B><I>RSU Award Agreement</I></B>&#8221;<B><I> </I></B>means a written or electronic agreement between the Company and a
holder of an RSU Award evidencing the terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to
the RSU Award and which is provided including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kkk)</B> &#8220;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#8221; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(lll)</B> &#8220;<B><I>Rule 405</I></B>&#8221; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mmm)</B> &#8220;<B><I>SAR Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a holder of a SAR
evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including
by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nnn)</B> &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#8221; means Section&nbsp;409A of the Code and the regulations
and other guidance thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ooo)</B> &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in
Control</I></B>&#8221; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and U.S. Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ppp)</B> &#8220;<B><I>Securities Act</I></B>&#8221; means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qqq)</B> &#8220;<B><I>Share Reserve</I></B>&#8221; means the number of shares available for issuance under the Plan as set forth in
Section&nbsp;2(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rrr)</B> &#8220;<B><I>Stock Appreciation Right</I></B>&#8221; or &#8220;<B><I>SAR</I></B>&#8221;<B><I>
</I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(sss)</B> &#8220;<B><I>Subsidiary</I></B>&#8221; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ttt)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#8221; means any income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in
relation to a Participant&#8217;s participation in the Plan and legally applicable or deemed applicable to the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uuu)</B>
&#8220;<B><I>Ten Percent Stockholder</I></B>&#8221; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or
any Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vvv)</B> &#8220;<B><I>Trading Policy</I></B>&#8221; means the Company&#8217;s policy permitting certain individuals to
sell Company shares only during certain &#8220;window&#8221; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(www)</B> &#8220;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xxx)</B> &#8220;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ima-20260616.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/17/2026 11:23:05 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:ima="http://www.ikenaoncology.com/20260616"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.ikenaoncology.com/20260616"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ima-20260616_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ima-20260616_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ima-20260616_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/17/2026 11:23:05 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ima-20260616_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/17/2026 11:23:05 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ima-20260616.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 16, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001835579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 16,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMAGENEBIO, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1697316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12526 High Bluff Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">345-6265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d114862d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d114862d8k.htm">d114862d8k.htm</File>
    <File>ima-20260616.xsd</File>
    <File>ima-20260616_lab.xml</File>
    <File>ima-20260616_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d114862d8k.htm": {
   "nsprefix": "ima",
   "nsuri": "http://www.ikenaoncology.com/20260616",
   "dts": {
    "inline": {
     "local": [
      "d114862d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ima-20260616.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ima-20260616_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ima-20260616_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-06-16_to_2026-06-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d114862d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-06-16_to_2026-06-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d114862d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ikenaoncology.com//20260616/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-26-274139-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-274139-xbrl.zip
M4$L#!!0    ( +6@T5RS,V_Z5A0  ,.3   .    9#$Q-#@V,F0X:RYH=&WM
M75MSXS:R?O>O0&DVB:=*%Y*ZRQYM:61-HLV,[6,YFYSSDH)(R,(.12@@:4O[
MZT\W>!%IW6^V9Z+4[E@D0:#1Z&Y\W6B E_^<C&SRR*3+A?/A)SVO_4288PJ+
M.P\??FKUVMWN3_]LGET./2@&11VW83'^(3/TO'&C4)CTI9UWF9E_$(\%>% P
M-*.<"0OZ;LZ;CID;EQY0MY\7\J$0/4D5=X3C^*.X\-/34UY5CR]8GBS@&P4H
ME(-23'(S>F]B<^=KZK6GHGI)K]?K!?4T*CI7,F[ T+1B 1_WJ<NBXGQ$4Z7Y
M5^90 =RQQ<,T;XH1TE_1*GHEIL7EBRB!VO7"'U\^]\PA&]$<=UR/.F;<CN_)
MI535"_ T)L@5)4.OKNA"6")^8;*LK YE'>@P^^/CW>=9<6]Q^5G1@B>IXPZ$
M'%$/1 9K*N<T(V=4$I7D0"12%44BLJZ>6JZHQ[R$QOFJKC[C(CZUGHEF6+A2
M"!Y&15WIS0LEW$S)H^N-Y6)!QR?)HLN%#]4F@^K#J 5_/.[9K%G+_7I9"'Z>
M78Z81PF^GF-_^?SQ0Z8M'(\Y7NX>Q#U#S.#J0\9C$Z^@JBO 6X6@0D+(95]8
MT^:EQ1^)ZTUM]B%C<7=LTRGJ$\LTR26?-+ TD^%O;EG,"7Y#D>M F0BW/F1^
M48_^!#W^L\=,7W)OVIF80^H\L&LZ FH<^!<:8+RQ^+FB=N+=L0&4\J4:V3]1
M1W):):=7_O1$XBK3O&[UKEK_<UE(43)'V:S1UH@Y%OS?^V33AVU;4SWDD\=<
M2=,SS0&U7;:NY6<\Z3@P:-,VM"^IW74L-OF539-,65)@2ZYH8"QJQ7*Y6I^G
MK_!L "4;, GVFKEPC>:KX2H3 VT=TSJJEM >?\BX?#2VXWM#B9T$NYF++&-^
MXEK14RI-*5!$U[=1"#N;ZJ"Z=H4O@TME(!HA=]5@;<#=Z#6FQBJ^Y!;>&' F
MB>(@6VB^VMU?T^/S_&6D>F']8QA 8<678+FD=T4]UIS1%KTY>S:CU5I2-GH2
M-QNW4TAQ)^;FC'N%I%TH@/V /PDK@F_EJ,T?G(8)?6$RDW[^Q"UOV*CER]RY
M2)2UV<"[&%'YP)T<_FX0ZGLBNB/YPS"\]:PZG!9R0Z:> P@9QY5X8MQ(7/:%
MYXF1NM,7$HB/[NCC"7&%S2WR3E/_99H_OM,KVL6"OB4;*ZYOS-B^L7'45*+B
M&E1#YKM!!C!$.9?_ES7T6GP]H"-N3QOW?,1<<LV>R)T84>="/7L**.\+V[I8
M,$R_77?O.U>D=]^Z[_0N"^,EY&@O1$ZOT_[MKGO?[?1(Z_J*=/YH_]*Z_KE#
MVC=?OG1[O>[-]5XT&H>@\7?J#@'P>L+)DJM\.T\,K5RJ/Z-KUFAM _&<2<1X
M.\5*"F=E)^',:U L+9\7@;H:^@_SW=]079,"_A;$_-/-W1=RZ8ZI$YND(?=8
M#NZ8#&;-)TG'F>92+'$E3!^A1 )F[0 E=",3P+GT1'U90+J:)P$ZD@ =1.G!
M+-UUKN_)7>?VYN[^]8W0K2]=GSH>\00!>(TB&+!,+Y*;.Z*7SZWWKT^E&)#[
M(2,A_N?P?N0"D);I$7BLUXNEY73J+T4HXB(DYXZ-A?3(>73-*. BYGJ$/4))
M(M5C9KUO+/<[(EMQJ\!5)\!<6QN-P-=%P^$U+*A@!*\/+3J= D7,21J58J;Y
M+]]AX>A7L@2KF;<Q)^-R#.-BE XA?<N%*7 2[]@#=S$$XNWB.2=DI91I=K^T
M?NY<=SYV;[*D>]W.+W ;][ :VB'8<=Z94+ .R 7401GWGE"7N&-FHO=D$>X0
M[KD$[ FHI'QN[4XBOES$]^#-V:5'^S8C)K-M!$\8^<UH&74]II8578<MA7TU
MA6W3L<L:T8_50D+2! ;<T#7MAXAW8<L-+:2VH45N(M GU;]6VO<LEG[ ,$'R
MP2.3'C>I';(WZ/#S0N';QF9O1Z3.E4Y6<UD(2931TS%]8+F^9/0K1GNYQ1KT
M48 X;,PE70W3*OI@=!>I6@H2/]?-%8 XL$M=QQ029D1E@'H>3%-MX3N>G+:%
MM=>4AR%A#&UX;"S%(S:;GO/*,&,SFS[!7+@437O6)L,=R_::XCOR;V>/(V#P
M)VXS>-:'IG8W^BI*J.=*FE&K+N76=\2T>SKIAC$V4W%I;PY6P6_3X5Z]6M07
M0*LY%AY!PVL[*OBN,_E!O.YS91.(D$1X0R;)?\ +<"VNO)6M8(9^!.( 6?"D
M_5( XH4TX'5'I2U&(^ZZ;V$0T,"10#__/OSOYN_RO3SIC,:VF#+YZH.0MI;D
M6N1G8Z%,&?R#H&\QA-0WB;^_*H94%!X"1):U@\# 4NW[@H$MRY+,=<,_G\$C
MTO>8;&N9IFZ4C0KY!2@@'VU_,"!7DC_.(;WL.K=YGBYC#[KJF6;/!S!"BJ7R
MRX'.UQ*44)"/)2MM^'DC[\63L_N(&!J,")!RQ=F#V%4X%$*YD;?@9G"5'G(T
MI\70,\TVL!+><#A](0DZ\C#>"NBO_7]\O)/#-V.-D6G6#;VHK>+*&P+5:WAW
M'G('@U=C"6+%Q]0F;,),WP,[!K=AKF7N^S?E=9W#*!(<QO=S3%\P_6\9HS](
M6' 6!?WQ7<W0JQ<N\9C-QD/A,.(H#)E%2&_[B" (!<$ B02I6&X*T RUH-R>
MXEL$]M7*M??SL=2=7=G/ @;T%KNVK_=JE#)-F+)R%:.R?-[:9P'F((-[+3S2
M&H]MD&,0M7UBT(?!Z)_ KH/'>JUBT)*$EZ%B@Y@-2%NM8UFDA_,&^4Q=+UP]
M.D6BC[62NT[28((=,O,K\8:,T#',PF!],0#1%Q/29[9XPG'#ASB<ZY53K=4K
M!2$#;J--X2X8&(\Y%HR[)XC+1[[M48<)W[6GQ 6== =3U4+X@N@#PP*W2@1-
M)U8S?*A'$NI,HV<#\&S$$[Z'"(*CA^XVEDI395>_ZZ!^U9PS-7.TYCVZ9Q[?
M1M-Y9J$+]</%ZED/A7*%>?U=<@_&$2,AOA,ZON[>X*\OA-VG,(8>2%S2!)=Q
M'.K54NEBW@)O-YL'_4K( TF+ -G;6L\U%O(*F)-D%ADG,A#N?! KZ&8HTEYZ
MS1^7^L_U*FE_NB-&4<M#P6T"#"<YWUW.>V#,31@%Y^$+&$*PAO;QA+SR+0OY
MC%%0=<"I>0E?.V/H)9K3C6C2F"E#*NLE4H6UM1DE+1_4^#X!U$Y:<W2MN94,
M9P;,)%=9?SCARYO!8 <8OK'V5+]E[5DKRL#1G)E@::0BZ^:4#33.RAGG_?>'
MU;F@SI/6O:;6=5W79_)%=*]VTKV==*_(<J5S\["Z%]:YL>X=.%@!2& &7 -?
MC4GP]L9+\VW14D0.''1WN;_V]A?*3LE6NT6--XBC+.G!G!;LM5I]C,7A>]QZ
M&J1"FT-BVM1U#[)0OS//WAR#)$5%O.S+0K,W'4&Q<_<PN0ROPJ)C1%.OPTQ>
M)4(LG!M>/>U!. 3T#RB:F?GT;/-6%N>7.O?AMFK=Z"LMW6.-H)YI(O8"EO0\
M87[-DG]H(&XZ&5-)'JGM+TBS?)E%JV5]#[4N4+C=.U[45$;\*_4N#8D(@M0<
MG^2"/=N-=1OLF[BUYIJZ%OV+M.F8>]0F7ZC\RF*$][+ J>M8""89Z4^)J>+P
M4.-7T#&FDO^>!;^Y2Z#K $BQT0?R(,63-T1,.L: .'6)Q0;<"=+\@_"B5HY@
MUK/88K"-J$C.<32J%RK$&!7F:H/ &#<(X#K.AL#6Z.?B*,Y\FXOV,*VO-*(.
M0>Y<_0DR\\==C<LT.XMY_N.[FEX'#VCUPG_T\L_JW7;PZM$\LZ(>>F:5!9[9
M<;G4':R03UQG7BCL?&Z19PBBS&SP&$"4':'\!]]EJA0P+%Q*PM--N%HE"K;D
M(X-46_84&W_BT#2JA0/TP1/)'KD+[X&"4,?$4"4U3<R\Q\)XSHE%I>4&BTC6
M2N>E>$YCYR4IUOD-I6%R'Y,>['<[GB@8*YST@WE<W^TI ZGUU[.SQ8K#1G-Z
M@[<2T*?/8+P ^MA/=.IF@LUB9Y?#&"7A:4>R\:ZN_KN(^C.>)-U*TV94X@PZ
M5([;V9I%[L.>(W'V/.+V\>;NJG.7:]]\_MRZ[74:T8]O(>*FZQN&W%:G_G0]
M-L*4&DV_*.<U8].TI!</?:T"]4'K5PP J^=+Y6U<<0FV3D@7368;:*< )6Y4
M[I5T+TC'#BQAJN@%)J$([G@8*,,G\^_AG,<<ET+Q*6E)B2832[N+BN?)-@&L
MRB$FKG/V?L4>SF"[]+YMW#AD?L]QEG1'(+P.^\@%_';,/#G'>05%R] NVC',
M, S]XCT9,MM2&SCQ7=)R'!_Q*V-J$@-6*D=D",,,;$Q5E"X:U9<G+9<,?*FP
MIL5<4_)^@!Y1O D(=C7( <FJR<Y-UAY.@.T(?&+JR".\#$I#HU.DX,*"B5?E
M=T;"D7@I3DG#D[Y(YR\?9D?D 6;6/S)R:T-=R4ZH8G@WY@?U@A!BFA$>L)*"
M7_80;J'Q\.@15^6Y@8T(@01]> #$@6@D2(-#VMPA!6KQEQDX=JK': 6'0L(P
M!QB#NP@,3):(W<:4(;2IE;4LS"51;<@#P!!!DAU;UH:J%$VL/Q:8-N"$)P:B
M'K()DR: E^ E1YD4+#I69S=AI#6D$UK">[X"2$\4]<S#[!M%(Q@AT[=3>34T
MX!M:>3PDS@R(PQ%C$@8@YE=*DD8!_DJ.0UZ=6/!\5#\*0%1IHS*DBL)''B3_
MQ$*CB%DG-3&3L\3U^_^!*E4^T4PHP_JHG3^Z,K="=1DGV1DO@L.?4:PA28:A
M!X=8CT9>FE*KT*:J ZULN!]R^E:*L7"ANF(#+:SJ6:K2F%EW2YBU4*7"05NF
MB\J%Y*HT-#F9DEG5*/P+U&W D6B%M_'I;[A/)^'Y(8$Q3)YMHR+PO]98<CLP
MB$4M,(@I6;M5!/0B I+B!IJ?' &59!9M3%.L!=%0+F)DR0Q4S?BP,Z#0-X?)
M*K+H/S\!RL"_06(9V >!'4PUY,RJ#2C'NK/$$M!5]%7 ;U#'84#[?1;X(\QC
M6<4&5*Z_?,QGY_'P<ZD&7C(8J"2%1'4 R/!M%*B)MTB>LF$T#@,#GD?!J;)@
MCH"Z!/:B,QGR/O>(#M[SG$HDQ'WG#>TG.+@8#E:_83C8\_NQA@[(%Q KG.U1
MH,B_17# 2Q19([\$6. 5 %MBOIF!HN=X:!'@4I '^I P/48MPF)!& +,B$7P
M_)@E!D^5 TU^PG]T/6M4ZUF]J!'A>RJ.H (*\2R_R,8^"D5@$@  73"KC8 O
MT\1THG@/I4&M%2[H3],@;#'^ 6O@,F6NP20K_+9R0CQ $O&<7.$*>CA[Z8W%
M;L,*D@XM(C'C4\R+(DSI+&+O2:A U2.W@*=*\@,T! :UC2MY@=!TN\2*>I+%
M0EAKN$N%8%3)CJ;A^CJ<K@"BF@A<WS29ZR)S<*JP?,!($958:C9W@& &C>!<
M%!RXA B>>L,L0B=0YQ#H8>!K%&"B>Y5B[0 EH?Q!0=_V@K:@=P$/W,:*F<(X
M\FK\86:2,.)16K\:?W86K,>?+=JXJA;DSS9>4R_&:^KI/QN_NWE3I3V:*K]P
M4Z^Q!6VG#7]1\;F73(&BZWS(&,^S1@ZRRKP&67P2\JC['-]HMW\'=P(G]K]C
MW]<NBWV4XBN3 =77PLDA,'/W/Y9&J6IH$@^ZA'_1I^;7!RE\Q\J%T6Z8Z-A@
ML'9M?WLTG QIXRAA,%X- 4SJP/Y&+KJY%9BXHH 'R&V>?!3@'-,L^9*_RN^0
ML+),/!<D-6TIX)O6D)1'%>7/-"O9>DW+5JKZ,>CZ]MA1TK*Z7CWQ0HF&;F2K
ME?J!J'JM#*&W8D7^)5PV'J(9Z=G*N9M^3R:DG"WII9/:(#N*Y6RQ>N+%L4S(
MV9K4K"-'-(P&N:.)PY]4."FU HJ?)ADS92K(W2PA_M;OV]PDK5GBR2>.FZI?
M.1 B56>B99A$3_K!ONR6;W$O"-V#T6++HEH+UGO@XE9RDSWARLA0^"YK"S'&
M-C]_OHT"[<_KX0GFI783*.8ELG8&R+PH1C?@+@@.P;.>"0N"<%?,9+BT%ZXP
MZ%$$\.\0")EM2ZA6]HN#%#>-@ZS:4K!YP.&T->&XAP<*^>WFV1^#(:T'BM\Y
M.S$EQ92^BVO4Z66=MQ496$1V-5O1BUFM6GZA7'1#RY:J"SS%HS16?C/XI]@(
MT@M2F0VO#6)2N21)ROYN\_V^ZQ[&?O/]QJ^OF>^-+1<JEM93.N&&$VXXX897
MP0TGILAHM6;]9J?YE9QO"WU5LD7#R-:U!:&>XP"BNI[5ZPL6+8[2FJY5LI5:
M[85:2P;-GD&^L^2V%!"*T\Z44RKBDE3$>E[3O^%4Q$_Q5KTX!3A*)U:)K>Y+
MYQTN<(K.K?<Q.:MR;-^\ ['M@?]I%V(;I%Y>@M3K+Q?A>Q$8?HQ3(4)1V_X<
MB W0%(F^:\\=M;.R;X-[??AS+=1NFP.N>VXZEMM;LVUXII0UA\JY%\=P.UZ\
MV6 E $QH[IQX1R<:PX/"TB?))*=7_++&PK,$M/RVL&Z+KT,T+RD92K756M=+
MM8IAL8FNZ?FA![7-;<>+0DF)?3;6BMTU. ?09>>A?-]CMF"]^V!#UA9PE]Q"
M]X#?8$>HJ3A^13U*U/>0SG&ES[+"C4CASJJN,F3DCX]WGXD5?F(6SXHX@>K5
MH/I5OV3:Z_Y\W;K_[:YS]$U\R>]!!UL_0*/E;&/R!D>81'M&4D=7J+Q]D_JN
MBD9S-_P$<K@E#)/S,8,_^!)KGPVI/8A6VM6.TK  [C'Q<1N;JFZV!_6[1IFK
M0].E \6$]US1/A 1L_3X8\1V-LJ0W^C P2USD8Y1YVS>*Z[W?^<^UKSJ>S@;
M3,FH54OF9/4H/2D?MMBK3/'1&.%'V!O)/735Z$/I1TG&/ZC@*-3P<=HXUL:!
MO;ROY\?.;#EO%=P"^57"C ,PYW\I3%CT=<_@^\:,R3'J;*;'(TMNAVJ#P&E(
M7F](VD/.!H#:HD^(A>?+; +_+PM]84WA&GQ"N_G_4$L#!!0    ( +6@T5PV
MR7>A[8   )&7 @ 1    9#$Q-#@V,F1E>#$P,2YH=&WLO6ESV]:V)OR=5?P/
MJ/2]75(5K5@>,CG75;*M)+KMV&[+R>GS?@-)4$), CP *)OGU_<:]UX;V""I
MP6;<KV^=NK% #'M<>PW/>M;/O[W[_>73GW\[/7GQ=#CX^=W9NY>G3T__S[WC
M^T?'/W_+?\+U;^6&Y.=GKU_\,WGVZ_/7+U^__:]O_O';V;O3;Y+S=_]\>?I?
MW\SS(KMWF>47E\U/K\IJD<Z_>9H,!_#\\ZQHLNKISR_._M2;/^33YO*G'XX>
MY\4W23K/+PIX039KOJ'/O-';%FEUD1?WFG+YT_UE\R21O\=ETY0+OC0KB^9>
MG?\[^^G8_SU+%_E\_=.[?)'5R:OL0_*V7*3PI9.79[^^^J]O*FSD-T]_?O;T
M].-E/LZ;!'N<_/SMLZ<_?_L&NQQKP?&#.VS"A,:$VG#V\_GO)R]?/OW]Y-?3
M5Z<_?\M_/9.K9Z_URBC1.U\]UVM'VQI]E\-FVGRB;3Y]]>+TA;8FD:LGK_RE
MMW+M]/S=R3M[ZU[:_>#^@\?)J33I?_]Q]NZ?KD%^<$]?O3O[TTU$\D9^>'GR
M:M?6?ZJEHL/^XO6;=]UA?_;/]I5WO_ENZ()Z??*V\^3K7]R5%[KNWIX^?_?Z
M[;G^\--PH#^=/C_]_=GI6_WE?Q;C>OGD^,$H@=%]Y(;FTV_CR,"\>?/V]9_7
M'9ESO?;Z^?_Z[?7+%Z=!K_];?OWCY3];/7Y,/7Z\WQ[?8@>VQP86\]TOF\1-
MS=NSE^$ /OB>!O"[/<NP.U\SB5LR7IS+DOENMQ[?B?S /AX?);_J]+\Z?7OB
M9N!HRZK]KJ<!3?:QN9<74QC&GQ[]Y_4;=) >XH>AW\^>GJ\FDZRNRRIIRB0M
MILES>#@O5FF3ET52SI(W50X_OIFGQ1$^E+R[S.BO)*^3!OY=MU\P:;T ;S(O
M24YJO7HZFV63)K_*DA=IDXV2@_R0IZB -TVG.;XAG2?IA[2:UC 0ZV2<)1=5
M"JMGFJR@_U7KY4_@%?J.M%@G;[-F515Y<9&<7Z85C,.'?#X?#L;9I%QD27J5
MYO-T/,]@P"KH3KU*BTF6+%<5_JO!_ISPI]O?A*[SY["_\$GWS?D\*5=-W<!U
M_&H:?]PVF9J45-DBS0L8R_%?,"+X9;P+-LFB[@YA<I!]G&1+=QNL!E@).!&7
ML:]#OU?S)LF+X: S'LUEVB1W-1R',+?0E\TW<7_'V8:^RIVX.WHWYR?;&F/:
M&J!E/Z76OEE5R[+._-)_7BZ6L+1&R7B=++*T\/,#MX^2.LO>U]BG.INLJHP6
M2)4U.+FT6;+J*H?M@@^=+I;S<IUE]2AYD5<P%&55X_W# 6Q!G#(8/_@-WK6L
MRJM\FL$4HN2$_5+3%-&$+[.JAMOQMNQC5C4P*!_SQ6J19#.XI^$[S3[5YDH_
MJ('XWY/9+)_GL WIBOEH*MV$_GZXS.&+P6=U4T*C"G@R*9=+^.JJR)LUOF2<
M%=D,5/M952ZP^566UM!Z&(VK=+[*3&,6):S/\Z:<O(<K5;FZN*1?:!7A@H4[
M>6'QLOC, G/B5L6)VR72G% HRJCY8:<.:#]GY7Q>?L#N\,.@V3B9=Z:3F_ H
MO%ZB^*NM2'L%?S=ILX*5LH[<I;>=G[RE"U>'( #KILHGN _Y?OXN_'HE-[\]
M_\-<U%>\R:H9FH\H /17DG57[BNOH4-5,">?>ZM._:1,2QH'.D>>M,X5/F7=
M#)'\(8&7%[1I\AK$)_2SY"T:O NV^:I)"I%\[2-H22*Y*8>#[FFV:9D>_W!'
MFL6#(Z<#_7;R]O2\HQG]\>R_017LZ%"O-VE5$5-KJX7[B345G&,ZL7!!@PB5
M.3WW1T@Z_6M5-PL\!T&XI)-)64UI]7[(F\OD'">F+$3CA=WLQ)Y_#F1OG109
MRLBT(N&5@X#.Z)5P)TCE=)DWZ3S_-VLV)_[)$2V<].*BRBY0@A:KQ1CV!FSZ
MFH]9^!>+N$0E7-KH8L*#%M=2]YBEE5J438+'/=S"4GP!;_O)JTH_/+X_NG__
MOGZ)WOPAPY-GB;(('H,+1N#_S__QPX/C[Y_4K *?%*"HS9/?LTR%+#7PLIS#
MH0W]6LY7-<JH_# Y'AT?_S Z_NY[_50.0CX'C6>-&@9.2J#@T&F(C[-D2AX_
M_G%T_X?C2#NGTU;W:3"Y82G(N@6,]X2?<T<(;M;_3N&6:BU*/>OT[I,JWE9+
M?./]CB8XPMFFDTP:U%6"X,B"C0V+DMH$_SU*S@JGEXZL G.ME91L6DC4I&NL
M)%HC;I1H-OK'")_.4OC .DLK.J%2/,CS<DH'%)S@^ -,. P%M&="2R(ZT-_3
M!LI8SX1;#O!/^/!\A5<.(X\\A+G)245(%^4*1B+[%TXP#,X,128T X^_Y.#Q
M?Q[J:<EK/3GX*'-):F()([=]6*P:C*(<)H.>>'C\\_D?;Q+0-%B$>7GT_6,0
M3U>@0.$HWB-OZ$\@V;YY6C<@!?\ 42ZM6H*JEM&+X488 1A)&DY>>.OKMY4T
M;5QQJR5< ^L)6E&+[60?*:AU>..;*IME5>4.];"WZ"Q^@U[?Y.=ECR'?D=2)
M%<UP.GTCMO+G]:@<)])R[,*+LS_AQ!&W-72&_@<]JIOU/ N/TVS1:0I>6J87
MV;TQ[(7W]\89K/;LIW3^(5W7WZ#K<(E'V6]OD_.S_P\Z]O ;?2^YU7_Z'S_2
M_WV3_./LQ;O?_NN;X_OW_],U%WV3IV__=HYU>'E[G7^J5?[O6Z_RM+XD>V62
MUQE[&;(9GAY@_?PCK5"_JK=MXCOOW!/5WJ>CY++\D,&K1GQ0X4//2M4 4Q#Z
MJOJII$MNTZ:4[:?A@(;8V%[NXTZF.[N/;E5;.DWF<-C T&R;AKT83]ZD/G$'
M6\O:&0[8D$E>YHN\89OJ5=F@\N;=&<6ZN<1_B(J ?J8*AQZ.E9:"E[*"]TE.
MZ%#54VO[!BK?<-!6>NR&Z#$'T>OV_>CQ#\>C[Q\]DF_MR2). HT<&IA5-%QW
M8BS\>),VY6ZAT3)*3I;+>9Z1;R28BS-6N=]T5&YN^B^PQR;SM,J;-4]WV%&8
M =AO] $Q&2.3CTZ<:RO\N&:G)3R/2C]_(>X#&27J ;P,M7N6".^S;&DT6;@%
M'9,-#5E/>\,!0EE3%O PZO;_6N6H:J!/"^:WGL&&0^$\!EF6\IK$_8.=&@[D
M?;9O)*UT>,7M&(Y$3EI/P5N8#39T.E47V$;042?0@IJ4;MRVL,Q@8-#\'J])
MBT]QEB?8TU'R*JVGZ;] BM0T8&]7T/W'WSU\#,L5?OSG^2G]E$W=>/V>DIT1
MR(^']Q^>'-W_01XX@9; ZPOWR*\K$,V@0=I'OC\^QJ:6Y!/Q#4JJ%;:*91$,
M@W.J.M,.1G8UR>*STN.0#8VL6[M>;K;3_%8[F<@BP*7XHD2QC<HJ3$"S0D&O
MS6ZO,1P4N?TM#T)HX3N_FG>:I?*I:2ECAU[2X8#-BMQ\2 8P'"FV^<DS "^#
MI>U>TS\%+2=U* CH?;O,$9CKQT9CRCXN\TK"(Q4YOO/"14MPA:$+U?TIKB?<
M%J 0L6%$C4,S#30+V@CBE/7/D2>+'KQ,KW#LQEE6R(9[DAP\,,VILZ:1LV_#
M]W-1V@Y^/GN:'^'TG#UEZ?@F1>TF7^)^1\6*_--T+W3RDH:!=X^;^T-HP<-#
M>AB[A=X&$6^!=Z!<S:>\I3[@H6@.3NBP%7I&--EC%*SIILK?9SC*()$FEZA
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MP#US,8S0[5.4NNFX\6N?JB4: VQKVQ$VRMVAR^U>U-E\]L3DA8?,TQT#V @
MDU+8X8 -W^*D?O#(=C9""U76\\7#;90]7Q<(R9U9_I$MC/";YK9(QGXX3]98
MZ>;\J/I1)\>/'U"WCQ]_KZL"EBLF.V?J<G9P 7R00JA2ZLY-I<?6!:KAM7H^
M,C#,.!LWTP X0S#45B33R  -9[:PMG$"+LJZ(0 F*\1Z8&N4KGUPMTQ IRR'
MSD=_5!/=J\\_($C%;*XA\L@B.AH.VAF<\'ZN<^N=;V /5FQ:Y#!4A7#&^Y86
M,9'1,DS7[;UV@.Y>@5.F3O?B7GN@)7I'*T(C>47/Z&F" (#C<+X^C$B>8!,9
M:.AP0-C0SY)B\0,82Y)B<?)_'/7X/Y3G_-UOO[U^^>+LU:^> 7WO&1=(M8&A
M;N(7$&/?T/!V$Q;9/68K \9RR=KYBLZ/4-/2EB\.!V2D+--U56)&AR3?B?>.
M4+&UK1?:#FMRU-.+!4IBK!U0$K0W,(\P.Z>J4!MWRF\-/:QGO .WJOGOTH_W
MWF*1W6RJYL-9@]@3TQ$+V0GR=5MAK&]I^PP'GO!1XEHBU&(N**FF(OPG(X-\
MJWJK6+?**!V!'8)2')['P%XX-9K\C&:%C+/[A#L ,:T[0?%^8;A?<.<JE6V[
M@AR39KM*97Y\2')1,ML.59P*[[-NEP4F<@P#E**4-)K7_/;V_RWR/& K/WMZ
M3@U)7;3![K+7KM$Q.S_0B0)1[N:B10IDRNCUY[_KBL<;[WK%2PEJW,YFSM38
MZ>B BRP5)7)-LB5(KZ!II3N,!HB\R@XS;*$D,'(9>\ "Y+Q5T6R3>Q8<.P#[
MT8_".!F ^UUQ-V4]"PK=QS>R9E+DT<91!Z@I;@0-VQ#^BH]>19[4? %Y>.TD
MIV&7"FLNF\;"2_6=.!\Z26E[H#FDQ]+4L=IAJVA?JL 0$KLPAP05.!!B"SBC
MX? NE][-XF#[R3L!RBU6\PM+=8]!SN27;$H*HM:#(%7D"4X(HC5=XUDDT-FQ
MR$!638VSMU-],5K)[7,?PQ.;U_TZ$)&@JZ%;#_KX>UZ 0OWO+(%MF8$I +>^
MS-,Q!I5)\WD^3_.%U-WSH,-^:&(H-9@ $8R^54-?"P5U.P:+EQ!DF04D#:GS
M*&F1'4ERP*0G7AE.$Q?RX5^XU"):B;'V)/'FP+-%N \CK:%\6P5I!T#<BOG/
M37Q6,@_8<X:!&THQ$VQXP!05$H58\#P[R'=J_T*GDL8J_<CA[G^M.(AB9;R,
M9Y2MQ/F-I"6@2+B,I[4=!7V9@[%.,0^#OBR ,/VTZE;]K!N>-[I/)62+HD<;
M)*,KK%^MX5JGLV%W7.'O":YJ4.A29-T.(]$*8Z<L;6/]&V/!85 (_J/*5HTH
MU[D+NL'XSV4C$?5#Q<N4Q*@9;H?(_V*];H^^>MUNQYZEFQM-U*RH?3E90Q$X
M>0_J$YS6%UJ]I8.(_H Z.<DKX>4C/!1O+U/MMOQ0B $-1QXLTA$YAXL)0I&<
MN9.@P3WGUR&^*DRLBH@6#LIX 8)R2JS[*;KL:HJH8!_(2*![KLHYZ!&P+RBT
M-IE3A(2]?'4)@D"JQS%:L+/#@Q'Q*3H*?PESO6STGH,/D?@5$Q8B277> O"T
MD#L4RD*6R[0&^Y]9ET2BBN8R0P?!@G-'*<-3-9=(6HLZ?;2ZL_@&8X 44E?.
M<.$6I*^ U02&CI(-NT 0NSQD)O.%+60_)2Z.E(*<X7*KZQ(9?;-I2Z-L3P2N
M,A+O/0)ZEVF(3>=GE-,AF9AS=&X9W1JTPT:+A@8L4;Y(5GN5D/9*7N2[7AQ$
M#H'[KYFOK[M2]AUAL^;J&;,CJ0_2U^IHN35PCKU; Q4EM5&83I.P5%S7X.8&
MZ-C7RN84O+19P4I:^T/:&D;H&;7I#*Q_K1:LH7(9N(HI0;R&3$FZ,>R_Q5@>
M=>A&$1UGOCWJ&*L46O$<<E4V6Q53AQ*$I^_1XTA/*/G@8O8E![3?"P254DGR
M(!'))]@3\9!?F%C[=Z2$>_PU+6;9]O[46?;>-\F9P_-RPB>0\[3FA+YJ]9PD
MQ[U-?<>B>U+5R=/2+E-)57+"ZQ:.B2F)E+DK\F") $S[:9UX^%'O\KVADMN1
M6GSH^O1^\UVWK&+?=S_V.%SZ6/$$)) B(#OS#,.F$2G:\'.A XYQ8<::4V\\
M#H0^;;86DHWYE#TB&]\(^D>U(.'KO!8@=>>(F=ZE060,JG@1N-?2^8R=>>D8
MX,W8H3%T\X6&H2%U,E+)2C-!R.O8!WTE> ZLQ.6JPLK7=7<C]C#Z$5A0/%#D
M1T/J_4V11J<7Q/+'T==LGC9.KURI45-TP7( 1C%%TFCAEE EDP=Q.+C!,'Z6
M8,R/1\GO&GDY?W[Z\N7)J]/7?_RM:K^>EZN*XRA4\-20]=7.\VC06 9*)X2.
M;K49G":F[*T*[[0TM?."-6GX&O5%MNI>:QLJJSHHI*H:[<I@]AGJJ__!J_,-
MTZ^)4#E/Y]VM>(0V\+.GX9VT#X@8KI?1)E)OB&:! $-,X2T0\@1/T78.TQX+
MEE- PJ?BG_"A\5S;C=/_JU)#VI+FSRVY'3XRL8^DHNFVETGHP^KD<(1"SI<3
M3-V J2+-'/JM-D0*)_21[:*RA3;Q7.I.$%T2_NS+N(V2"=(.DFJ;D;T"C<%3
M,UK>C<L?+F!K35+-=2+-5DY41Z[+ZB[G$(S7'4G?TJ"<=>/["F\JJ=I+=G1Q
M-)+(NR9PCBP"FC39O(#55Q\.!]-R0OW2=K='3U (^C-/( ;]"=!+<2;Y9+O6
ML!9?J">7V73%+$CM0^@P<3EZ,4AVZ6$;;:@$"2GVRW&;M".UYFJ0HX0<NY,Y
MJ/ZHEX*5S%0[I&SL_LI1SV#K;D;F3A?-[*Q="6BR^P4F70%[E;*P\@I3^B <
MU.OW^@L&^#W^ZFK\=&:YH9>6HD[*S+Y%DQQG831AQ(PN2AKMH[3*(XL[3>YN
M\;9)U<6MH7MCCW1B]\[WWW&1HE?2Z]<IL:X;W/*LK)(X8[D]GM%4(&G&2 QG
M"HXX%_8@*+YN>?$ZOIUX?_):L5:>M4"ER-_@U _(HMG!QC07+@]0/6;A&F(H
MF$D('D636P,2(5L2]6,VH8H2C4],*7M"26W*$S][G$?EA#$2]!)7?5N1((X$
ME;FV$ -'B .5A"#;QC<E79RD8*N@3\ 3Y]BBJ7YML3TM^+^ Z-B5XPZ_EP2?
M(Y2"JQTAV_.@H\<XWP@/71BS/4R4^A,!EJS8J'XU6Q$GM:N/M$02?M!2FK6X
M0KMP']KV,4ITI?\W&R1S*TB4._79\@O*RC4+S$WU<K=_>HZ5L4=)N/5J688E
MEWG0[/!.D=$0S.AO]"X4MSC5,^Z]#ZW9()7-(# Z[7#HQ'8KGJUMJG;OZQ7#
M9CQ0W50TKWW ._4B>83K1M"<UTT!'PZL?S*,79O&TJKV.Z&V(%)&C?'6J#-!
M3AA?2K$/$=$VL@A>6B$5(^>%<N(<%UA>;]R'88AL)HS=L"M7C%27?;0LN7P,
MG!YRY4-9O9>JLJ)!R@]!?";H-.E]964\B B%,#NI\JNN4D'G91J"H\"8G.6-
ML?Q=-)K6MR5TX@2?]I-TE@IS@R8V5ZL@U!/),/*S*(XW_-!>SK&9+QJNS/K#
M =XIX&."[71+?_40]Q#4J/+5^$C&F\4CB]H4Z<.[3%A6YJMV7C'+3I+:(MXU
M:PC3U009?EEG2='0'052W);&$#=E "*KK;!UF64A)TKFI?$EF4J^E '%1M2]
M2F[#>]1G]P!#L^"+K>M" 4*?)U B0N_G&1X9*"''-8:4X4"::79G&/H*0,%=
MO%F[<H\SWTW5FQ (.1S$($RE/Z4X%LF4K?6R%(/,D3W(S';I"82C6#SC+9JI
M:"6;1/'J:@=3#RE9E3;>!)-4%6O7'2!V:?AB$^$2'+40!;C<YU*)2:6DQTIZ
MIW_J^SJ2":.O.H7 4SL[\STD2K; K$X9/>6M,A_9:!FS'(HI%V9(O;QQ(UJZ
M+8-B71?>7B3/A4\UI!-+&NW#[,D+9ZIO1,EOC!:U1Y$C*F26R4'9CH]YMTAI
MS]46"R+F2U5B[P08!<OU8PHMF$+GW;)9H%RG544T)C84("UH#"N9KQ.^@?&F
MAGY5KM+.M^I!)E\=0D$QE&LM/HJI4>R)5)*TV=8#X4W[@CTHWWWUH-SU?K[T
M^QFM]JHL\@FFG^576<4GJ=N')O.EL.SNG!'ER+TU?RS@?$H5/R)\JXH:2:UB
MK'N8A29'8&2C1V^;<C-A^V:N[8SS 6V#3.<Q2'+4[N"5'SX<P0X[NBBOB,Q(
M9#?*!K3%LC%HMIG:V(=T,)2UR6IKAZ9S3 <KLH9>QHHMG9W0<=^89)%-\]5"
M7:?S;NC($5JT)1ZI+-2\PR.PKP*AZ32(UC..Q[#QY0V\7(0OFY9-[103Y$!G
M.0N$87-946(+\:!N-;S [D(DG 8TS??J-8SFPF?U"SL_9L^CB]V/3%> 618F
ML++0HY4BX7^=B9^I]TF&'VL6HNNR'-V!.TN<^U)DS08_^,SU/8'!A'>8, BI
M .KGY]R>:*'#?3J^//W&<S"K,9#][=N,:*O6G@0@QC0?J282Y.Y/RM52C81V
M.JQ@X.ASL)U@+ZY]2$=W0!Y69&8BP+:# 59,(Z"F8IJ*,Q&?5LX[>WIZ0O'*
M(0-S+@C7L?O]\6Y.WXK*Q]3JTR*;)>*,DFE]44ZG]WZ!,7N?_ /G_KP!6=4D
M;S.N?%E,V2VSP(SSJFS$E#^9^"!Q2X-W5M/6L;-8?QBVNFTG&%46WVFQE#%/
M&FJXPX$J56UK)%\0T,%DDFC[J)Y<R5NKLFLB).3O)FFU63%EQ[2IJSUWHP6L
M=>EW2=VW56Y9W\X+IVTC2L-3XKC8/V]>LB/C]5_(&"I-L9&>4NKDRSO"H(,?
MD196E0=>K)/V##L.DT*LC NJP)U0#B1UL)=YEZPM TKV?E7C6V%_L<M1JH0^
M0+$_1-;!]/,CA^NL.$="#W#/ G*5V102<S^=K5+4C;P]GA-8Z?/PKHYG,I20
MGQMZ\I>/)7E9@-O1D \1+N:D:^!I?2(&EI@H4+CVC+W#J6$,,K<^90>3PE@Q
M:/Y$%!4XIDSK1(B$KF.;;6,.(8_\=6$=KGX[S@)4.4=L+CRO6Q!E$H,F;(/P
M@ F ?@[FZF)5<]*ZH.GB<LY74_5Q:O$2QX=8E1ISXJI[2'MMA(COL1:1Y0[K
M9"%81VA,V[986R[N8SV^=^OQG:O'"$/H?*T>D_(D.>.%9Y%2/MU-JIY%^,25
MX[*Y[.5J&/44H'&/F[0OK1M9Z<&)337ZF<5YG#@/D)1'[J+UW&YI@_U&B4,W
ML.U+T0G/]ID8LD]:3BJ,4B% \>XGV;'R<?J09&VSXM-*,O. P%DE;D+JY"BY
M7"]QC3-:9EH6]%\X%L2S9O/RIGFMD$%2@(3:V;'1:5G9@*7%<Z1/?$XW^[TZ
MO+GFV%6VBHY'&]84G:)O^.#A2D.15?^9]=1YA\FJD,"L\\$^$Q\^KK[:0^Y=
MP>]N"+5#OV %XW! AV+()!#R!XQ$JW>"@PQ3 F;9HWU$9<?@Z1ISRF&]Y5GM
MZYX%)V*-/"=3QEV!R3I9<9)X.Y1K*C53GRV[?J;CH3$-.EK1QPL&;02C6(6.
M^!'Z$55",.\V"0.W2CM2HPZ3.?WO%:<>UP0NT%JV4E5A)+QMS)[M0[T>5M%6
MQ-L-=3]$.WQ[YO(;+=.%(9;BG*1Z*V%!+-/8%UV+,A,$00"O_AM#ELE?VP6%
M794\KIHWZM:T[UGIM'^DXJ_U2?L]Y;BA1,X+324?^\ZZU[1V1K881O<9.6$E
MC8N,:B4.'V>.4L[L )A?-\)..\;[$*';,3A9=PG5E4Z6W!?L__S^J__SKG=R
M8;5^6NZZ1IX]_:.-0XEH4K->M^?(ZTBNG*.M2:.KV5$M>KYCSE"I&R='-/O>
M5DF4>I?OA6LNJ%+?4MD\I&!C_BCIWFT? E6+*>7!48_*P262MFR[LUG<V'?Z
M37AJ^T8+"99M.]7-%&YI8I8V>F.D7[$8?MN#9S 5ECW,:TY"/,G>D:!\!YYV
M5V4^%0"+22[V%7GRHMNP@_3PX/C0GX13"8,W<7I;WW8,"N:4V58J.CED*O5S
M-.+>21<J=M>/UP&X):S62F7F(R-V'9:T@/3Z@.&-DD\:J<IHD1BJ;?AM=^@P
M #W02BJ\I[Y^^/Y429<0XAAZU24=R>/PE467(32U>CGT?",0C=/PU,?!R[*;
M?XVX!'V#GWE57/3I&2.H)%88V2HC8LFP-0Y-G%I.8XG,:XAXND*]",F Q!K2
M5F3+5.QXYFY@I(8VA4L'S"0$.AQTNQ3!U<TI,9?\/_1L+F>XV["'7K:Y3)ME
MFKOR;2[N[P+<^4?0$PM86)S%7^#O:\N-V48*Q)3DW;HLF9^@JL]SIHH$Z:7O
M;IFI[M53D,>7HP!3U#<_$ZP6([I,1USSMA2BMQX!'- 4U:57M5P9:QQ*>O5\
MM8#S'I-V-=%Z+;8M&Y(ZK,K:DLW3)278>;D]!D,%-SV]M/%,S.K>!'T^)_^Z
MP"/V8A66!NY4"AP1=&CA,U8;4,6-<Y^[\KIK1V""2YG<CT)WXF27/NSB-^R<
MDC050W_,HKRE>?()DVO*ND5#GC>RMI33<Q394ZYB$]R'L$=?4X/7#3NN)-=#
MRCZ*<]^JZ(28;!SY*T5./(A26S(<:%,^2Z[A\?VCY+DD&[[^\_35R:MWYY[D
M4:[_TK[R[K=3=\D]_?N;DU?_W&^2HC6!:4-2@CBR 8\I58A$#J$R#&R#@$RN
M/C9HW<5D;<LM!-D([B ?H3\*%VB 7L5EZ10^+ :!/B&7P^W?:8-JC#X3I5 4
M#.89).]8AMV('ZUD.%HJ$6<V&F3+1@[>7)P63?J>B7"=+Y?:UXZ&J\N[W^'M
M()X68%MZZM4(-YW+%0VXU]2CINBNF3H&.0)"#V0S9$;C02.XN/EM4M8MFD'J
MJR+'[((P2+&-BX+>9KA;^<Q8@4(Y9WJ(T-7=7^75(3%AH\]6<^_SIPF7=,YP
MIB,0K&"ATYJ"P^M*ZX*0Q'%L:S-"-W&:>G=Y[;RH#+.S28X9#@RSI1\?C,N.
M&3YPE)RT(:)D,X!QF=OQ,$#, #5L.$F"O)?>1%>OR.;2:GEU%0FPP#JXRLNP
M^M4U8@QW)XN/89Q$FKYX<?;N[/6KDY=.SKZ57_YX>=J1T+^\?NLNZ1O^<?+V
MA;_Q7)]^]M^GS]]UY/EKO0):IER#VZ !>CWTT-RV;M,ML\]/_.$:^ ):[G62
M@K#4U'>@*B2I(95Q&*"@1N*J;.I=L]UR]7TQF&V?9:4%%0+&\_#?[HO]9MHV
MZD<)_>Y61X3,<X7^**_V%^MK^^&KK^W3<1+<=$'!DO=^GAU(-KJO.4?EA(3S
MB2&^CE85NO&R)Y-V@S^*K/6F[&CP.P#L=NS02,2)VL\1V4'G'8L/F!@AZD,)
MLI\2F0)0$Q_AC4?^BFKDYFJ\3L%V)55KA=R>TY4KTA@Q\C&40KF2Y:IV:: ]
M089.SO\V0<HFY+3,A.E_,LGF&?D7]561S*,;K<">]0#-0I:L*P>O]?ZTX<![
M:D*\"JDU-YX+MDB;T!HEW\+,$%B_ /V58N0/CW\^_\.M.;^ OG\,Z^D*\9B3
M='Z/)-A/L!2_>5K#]^")IRYS$+F^IFF5K+-4RR=PJ%:JL7B%2P:='3]/NAB:
M[^Y?LRW-I;0%73#T:=Y\?5\F;]8^*[$-![#56L;<S6?:+>?ZTZ[C/OKPF,_N
MO.4'E"T]PHSG*2]M[;]K/]YL9.6'C$$6F@+=(6)QUL3MAJ]@\CD.98S8GPT]
MTA>'2;XW_TSM,N6"]M.W"^M@5WM/G*1&.$2**MRX/2XH?8W9ZQ/( ;;E[A2#
M$:%,K>QL";0[%A3;_- ]HW*4_*9>%PQY"+>>2]77625KU$<SO=1O?:ZEOU##
MK+?;9V?62I'3$^!J)=/UAD9J!S<- A+QB-F#PX-GAW!^A'$S+FZM*+( K\.=
MW"'X<,V 0Y^$B<48MDXMA1BX480IYAB!8,)VT RA&_>H&[J@V>>_IS/&JW/F
MC+G).:#T17L]8N*PZ][IO][YPG5Z.V>,#TI]ND.&BTY]@J,F1OPKQXR &,V
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M;6YY!.Z@#>Q]2%<P6VDCH$!,B73ZW)2/J8B_(E]@PCW<@F508@[-.QFB$P^
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MT_KF-?W*0<+W5FKVP "V!E8F!E8+^G'K";F=^M,F1(NOFIY])T.]6=3>T02
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MG(H$4.7ZZ6G2*U_WHQ?_%3T686Y:XIY_2?3JI5AN> A00@"H$_E8^%#5*:,
M4E4VNRISH/NQ>\ .8KLV>GN0V4VB!6WIDT3[F\>3IU-?G<(_((IH)U,SS-_&
MUPGJ7MYH (K>\<OG7"OZ$@5-Y/5E6<!F06$JZY]KP4^:.HIWWG%,1GH#MY7B
MMG#$T*O0_)O :BOA:*MQ#%"AIW]"LZ>@I_H#N[G,$06%+=?JG:SBT\!EG!A
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M[[#=M<C:YWY@X+2G(X* )G7<IPW8U["I&LZ82LK$"4H7K?7XZ^X8X@",F.I
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M^V<#/8(!HAY57":!(E3N1OC2=#5I]-(3(K(JZDQ/BAI_PCO('XAK_@E" /
M$#<@C8X_OI QO:S><YMY%N;P;GP.CD.LQCH1[P2<%K#L#R26 W,+E_$-BPP-
M_,,GDM,F*_T)BUL> ?=/GPG[1!)BV5>Q]#OU":S>L>D%/+V"U;# !RG I'6I
M;=JXK#E=<GY!X>C (;>J<%KIQ=H[/U<\>S@NN#/;UY_0^$#K)@CE17 R?0%6
MX <$$L[H(5Y$Q#K976OCG!(9X9LS3I@I+IXD)C,'1#=L!A!#=="I9)Y#;Z;<
M'\>6R E3'%,MI@8K^83$P!QE,"XS/=Z>B$I>9'.$$,,BKXF<$@[HFN1SKJ45
M,5<\K2:7X<]"%(+6 %Y-%_@X7T-^43LAX]44%B_B5-,+9<'D.UFVSN?I&#M!
M4=O+/.,E63_Q39@P V,=NLN0>-0Q6K.BPKP>:35.8=3NO?XXS]9*Z?'@_OT'
M3T3 T,X2 W)$3)KKNM&MLJ $.!&).:*D*5=,PQHTLIE&)Z'S?Q&<%E5+^ ,K
M2.!\.70DR#CTC^&[/$X9SJ4JZ Q\\5^KC*_C9..47L .,W0LM:1+>VXS(_>V
M"B90'KC -=QMX7%;'P0CK?ND+ ]=5-1S6E5X;)ES/3#3ZXX)37$Q$@YD87,6
MY'CE3J=-E:)$X.%HK9"D%)'35&32+J!)>6^*V[I<\I&RM;?P@&]0*,5)+E$[
M_\(BU<,!TH^N*L/FH8EXQF]!B]CQKQIIIC+8;V#34+8QP*BFV(K<Z1-S%A3J
M9BW*OK)N(;YL34[AV%1^9)1IR%[(F?KH7L[W%+SX&&,!["AH/60-??KA*-!.
M:0 #;H%@@%RJ=<108X70F7<QC?-H%W52E^\]L*\=OT-[.]@V.X0J)IBBYB8I
ML/!/AW?FTGKNSCJ[H"4WTL1M@5.GX[J<8]TB0?)57IM3Y*!=1>4L5.VQX169
M<$S^1(0BPGG;_QA\(KLB6E!8_L0P^0?S:&!O.>7 6$9V.CSBO# ) (:RT80E
M3(* -Y5#'&UAO5#3<D*)OV3]D=W!YFK<^FA_*7(']-2LJU';]"$3&S099E%?
MI.]16_IKQ1ING3AH )QE[!1(YQ-"KV@X*-#'=K>/ H*0@V.?ZT <WE.JS8-)
MT""]V4E13+]U8JPH"Z^+@E0%S1/$S\&#SEL\3P8),"8*QUL?=F\E+X)DGBA9
M.-?ZDO@P)G9-$&J/+A:FA!:2!U",X,#%]S[:^EY*P')A)SO6#5775F&+N=7X
M#WSKXZUOA8T.&^>+]4T>?_5-WF(XGZ)S0IQ&<DBMBE4-Y[D>1K"-A<0 ]] $
MMH[/_IRA]PBZ,E\'!9R<MX#]>M?8 ]_%5^LTGW.A.+L9,&Q3*]("VD:*2R)Z
M"[[L>_\RL,!7"_&^X2YRQPK:-K71*EQ DC6M:7@*4) 0GR#I258K$@B2;:4N
M47S+.)WKL1$58-Z[0N*;&Y$+_\4/FW:LB@%7&Y"=2P$_53S/ND-$S<X&4M^R
M@@Z6&HPJ)+_FL'NF&":,1X6\$"!!V=1T5Z+%+7902>LE+-YR-G/J:.",J@Q9
MD4\@=\5Q5"7UDD^Y&H0OSNK<)(YM%6W'O>;3H]@\K=ARUY'!I?3C5BG*@\8Z
M45 9P"&+/DC]WW$)&RRSB:)M[9_N(!49OWU\/W+"H<\#CUC*5V,_+UJ[$U^W
MP>?/VYV"(V.6FW$9MQS!XF&Y_AZF:@K'W5.9X5)E.67=@92X!HMJH/)%'C)+
M>"XG<[=Y&MR%)8@E"J[;OG8$('#3>T=J62DJB[00 6Z[ U?.S%OH<)LUMR2J
MN T'-]3<>CL-YCMH8,(Y[A*VF5<>[,^,,1RY%'[%NX*EC;^JM\SAHM'01XMB
MFW9'^T)J@F1B+&O:;$M3#(T7YPQ'JY6,0MK:2.+K:-%B3G4*'--V<$:T@\4[
MM?W_MG=NNXW;0!B^-^!W\*4#)$6.-RU0(,T&Z$6+!EFW12^96%E[ZUJ&[)SZ
M].6<R*$TLI3$L>)B@0+I)K9$210Y',[__2'7#_TAPO5Q/>!"K;N4V_LN""N<
MG'UN:,T_SJ GT!05S^3TXJ"FX_#"@PMH?$\/XJ0/4BOT;)&>J_=ZC?E@V"'$
MWFNNZ?UD_I!I@^2T)^EU6+57!3-+RB)$#I'R\I$ A3<PZZ3\6#0ANHHBUITI
MC<5W1D<+ZV.09;CBF5<@ [BHF5\R(<#M7HC$_"X#,@'-WN05S"NV&EM^U/]:
M,&DHA:A[N'Y\L[#U@W-B#.,]@+(X3&@>'QZ?#2XQ;:V+[,C\*8*)612- UV.
M/SNY%\[D3F-=R'G$=-59I7"_1[HP_5SN X(3%Z7^OA7C _0WUL@OF*71*,89
ML2G$L_Q1#B :PZS&#XS=L[^'!_Y'D$9S,G3!,J.D *XL40IO#G.S::<LXF$D
MB]X-X.7&9&E?^1#J8*0D39?RAK<<Q118)!5&F8,*$#$,[UV44+#?>9GF 3)7
M:A-5')7GD%2?,IQTXTQ[:R*YP8\60C,_G/])!BUVFE/L6Y9K51.\AGE$/B=8
M=X$NU T@]( =%$8B2P\ME0ACB3VW1MXE.5-D+X=V&+$T#M&0KB]KZC#8D&]V
MDV(>FT#@*]]#B\&Z\=KV=X&1^2A5LY#M2/,0C9%Y9V-T9E(QKXH<$]#W-9T/
MXS4)ODN*#QSGIG.<WO%&Z'>O9'MT=,@PAU4%5;'#97_'WU)KF\< 6AQ 6RY0
M+;HNE<)>?SYO*!"LQ^Y5:O#*9:\M*_'<7C?#WA=&Y;6YD6_6K]5K%OH])5JH
MD7VTEB_4?5\IW)HNL(7BK>80+U7 H:G8JD$"9\ 5UYQ^G2+.S]L;$<,UWL F
M<1SDWCZ,)F1BL@NOL?(,[MIG?/GM7E_EK"199 ++4UTICQ']GN*'A@"#>XY;
MZ8!X4O9V^)Y)O6+L*_6G$$U!6):1#9.&VHM."LVB.,(3L5CVM)CJ9##NM$H8
MSOQN0 6@87K"/KB%A3@%@I6331R:2@,$L=^CEOW [?YI,^TF(UM=FRLGN% G
M\*_J78;F1#?.'Q$>3:$2\I45H;2"K_3.36>P80.PORQ;!8?'P) ./3AF?4.=
M@$))T$7A;9-6?E*MA'L\R69C:ER0T8!Z1#$1)!C?%YT>5<I2G,^ECH'C?/FB
MPSO<Z<3/L:]+?N-G=Q?UE]O'VEE<NZ#Z:_*?]1]L1VN*TWL1QS/J?EA2 5O@
MR@8%GD/(:0F=#J);O93Y?\8)7TV:5M1A;DO<F 0*<R4$;:]MC-_1 4'U2MK$
M .%;[R%\3V=]VJ%,S[B5F=ZX,SNE?/_;)'J] &)G4PYY^H?CM,&_J ,E@,88
M"J3V<H5P@J%8E/2&+VARI!MB(H8WO6O2P-M^(#.3)X57=WIX5G^;X:\U]\[*
M%6S[LOXQ63J0@'R_=9/6>D.NL]]KO4B"AJD!,&EGBZ$//O_^@UYRJLIHIXJC
M^[U-C7?IC=BID6[.G*)2#Z0(0KG9 +TM^5?D9MD]M(K7TE"QX'JIO2YC)?*7
M>W8N694M+W<QF7?R+9FW>:*4A91Z4;<=7,1"K@O2@=0ZV<HGL<_FT?.QX&F2
MD--XC)*N8)]+3DI?A-%4^4R6MU'*>WLB8W-)V+8.XO>P5WG?$IY=O_=FH-W)
M<+HW/ M<NN%K&8'=#'P+D[J5!@7M?7ZCO>^)WJ+IBMMD@9LP(05)N*QX6&=Y
M4S8]< ]N.L.Y%>;QL&XM^]DL$Y5V:9/F."Q"MXYELKA,G'[43*1K6*,W)0G\
M/-] ?)$1H[+DQYA'G]#_EZSVA7_TIL7^:3<=;LDDH]+="I;!-2H;2[:E7(65
M9ZZR$D<!*49UEL-LOZ<SJ:+*I/0,IQCSPO\-(LO$@A:J)5%.#O5G7]%&3 ;0
MFYP3/@(Y7X8,G6[7<%KPM<#SQE:B)FI?5PU*B2\7 E.T<SMS2\RGXO]D]N$Q
MJD1J#I1@8??"?]%5]'MT&4FI,9QTXCM=)H!(P>!P/G(/(9.Z<74<'83\5)#>
M6&^:V%J_SN5]$.HP]&)E@CAJ!N:H]@3U>;\W%-D93["P88S%7[F4CBTDCA?P
M&6GNEEH$CA,WERKCK)ETK(Z 4Q9QJ@7X>^2>#JY)NBKS,E@)U.Q#D.$URM%7
M[LGWS1S-]:9S'R$X=)A<N&<?T\SHSW=091\YO/B[4)HYEZK?^'0;HPI_A(,B
M;2V5][J"+ @AG(#"0Z+AB>BSLD2+XLWRXTZJIF8^,,$ZY;A<Q&HOA%U5UY#J
M!!U!F$P*TRA#N NL+FCJ:,5B!$"2?XN7J*='%+0@OOQOUZ!WC[6C.(22>X)*
M()..U.K[*'+_B/D@AM^#LM\W[ [IX<ZP3L===[1'$&%B)X_AP>0%C=B;^2KW
MO:;&W-6*Y!?X>2'>X"3%P)ZHYR51&=@1AULA6P1SWWU9[2+?XV8]^N_GC]*
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M(C._AFV9;/47%O -&3#1;N.BN.-*;>EO%\IVT?0[=M2>_P%02P,$%     @
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M*31)(P@O U.1A&&S5F]6+TC_@=Q1G8(29,02V-7*^5JQZ2PE/T4_DTQU*X4
MSF%-[IF@(F*4DZ$U_ OIBJA"VIR3@9%I=*E!/4-<V4;E3'QNFG]CXYV\?4/P
M#],H=%;:\DPRMKE8C16O2#5%N]5Z8$7>KF9U(%K6,TEX=7459%?S]34KJHT-
MA,%?#[UA-(.$^H@ D45[3:&;./U7O6ON(MA<M/4U:^HL4D]&6>Y/Z!8Y6L-\
M\FTUWQ3Y8<VOAY65CKT;T^0FJTIR&,"$F->/@VZN3?89!)4X-KF<KK-AE8V!
M:B-L!"E=22&3=6"$P:V,%@F(U+ZV17PG4I:NNV(B59)UQR-99ILS!9.6QS!C
M-ICQ]., XWPZ)TZZGN-70[-DSL$CP4Z?Y@K'CTBSVCTLR E@E8*((;9AC/__
MLM<W&[S;,2RC7!;LESACIR&J3.5S$ ,S+5Z8-R9'%UE^\,.GCL1YHSW6J:)1
MFL\#-X-&*EO(Z1AXRRL0!=_3T!"BA<(.WZVB&153>*0)G.JK6)NWMTNRK:)<
M9*HB&Q7?'F#,?QVV-8(Y51C/CV8X\UGU1,FD,%7;UN1+?J6*0;6\6JV"LX%'
MYHI)4PE+/++0:$G.C7G*S368@%(0]S9).&HV<XHSJX:LYG=FUL:A&IOA>L_I
M]%18>Z+R4MHS:O'4G<&SF4$ZV -%>1=GJM7OL#X5TQ%Q>7$=,6RQO7,&F[T'
MC#"-I]+*:\H+*>_3LFDXQZ8/Z!5OT?$M/M2>"VE/7'Y:>X8MMDMGL&WFA@%,
MF>FH2,]YN"C6EA=:L5_+[%?'F.%Z3JJY5%EJAYAAZ,@%3O'KCHS/1/B54&4G
M^A7[%O"58X#O&8?'13(&=1[-75W9T>UZW7*J5QWC-**K;HQI8!.VV5-X#;2C
M0<I.\*AQBS-T#&<[CC')>OO28P+"\U 6!B@[QD+3%J$[Z^YCG:E]*\*:BPAK
M7Q"ZMC;?]J*#;Y_42"[%JP#NRAW!MVO9PG-GA9[K2O8H]J3Z2CXSLV?_&H('
M,1S!>.#;LKQPDV5?ZI3RO]G\_-5%<01'..ZYMA3=V9<Q\TE; 3V'6UY37E)Y
MGY:-.YLOYD=(WI])<>8Z[U!77D:'7BTG=S9<_D1_*8B.3)*%V"YS]*FPCHC+
M2^R(88O-G6V4H>0L8BD3TP>\&2MFK)WXLVF!LKS BMQN:;US9S.EK\ ,.<"G
MI>QW$'. 0#U-)J=/BR]%*"^]EUQ;BN[LH>SUIJOU M2WLRR(XPS1 N^6JSL;
M*_9@1E@;CUC*SSZ \D577FZ'7BTG=W9/1HJ:0X[#=3*6)]_N]D3E);1GU.)Q
M;7_D+@$UQ7Y\4'*9SG"NF%-QYO&3(R'*B^Y%VQ:D:YLC=RL<D4(S8VYS%.!,
MB@7ZTB,L\&SY_0_;(M?!05YZ6&!.,&^NF'_F/"Z6_ -02P$"% ,4    " "U
MH-%<LS-O^E84  ##DP  #@              @ $     9#$Q-#@V,F0X:RYH
M=&U02P$"% ,4    " "UH-%<-LEWH>V   "1EP( $0              @ &"
M%   9#$Q-#@V,F1E>#$P,2YH=&U02P$"% ,4    " "UH-%<\:.('FP#  "D
M#   $               @ &>E0  :6UA+3(P,C8P-C$V+GAS9%!+ 0(4 Q0
M   ( +6@T5Q>KZQYKP8  *-)   4              "  3B9  !I;6$M,C R
M-C V,39?;&%B+GAM;%!+ 0(4 Q0    ( +6@T5RFS:#9Y 0   <N   4
M          "  1F@  !I;6$M,C R-C V,39?<')E+GAM;%!+!08     !0 %
+ #T!   OI0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d114862d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ima-20260616.xsd" xlink:type="simple"/>
    <context id="duration_2026-06-16_to_2026-06-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2026-06-16</startDate>
            <endDate>2026-06-16</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2026-06-16_to_2026-06-16"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-401">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-06-16_to_2026-06-16"
      id="Hidden_dei_EntityCentralIndexKey">0001835579</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-412">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-413">2026-06-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-414">IMAGENEBIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-415">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-416">001-40287</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-417">81-1697316</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-418">12526 High Bluff Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-419">Suite 345</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-420">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-421">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-422">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-423">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-424">345-6265</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-425">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-426">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-427">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-428">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-429">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-430">IMA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-431">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2026-06-16_to_2026-06-16" id="ixv-432">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
